HemCon Medical Technologies gained Chinese regulatory approval to start selling wound care products in the world’s largest nation.
Minnesota-based orthotics company Rotation Medical appointed Martha Shadan as the new president & CEO.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
HemCon Medical Technologies said it’s filing for Chapter 11 bankruptcy protection for its U.S. operation after losing a $34.2 million court decision last month, saying it plans to appeal the ruling.
In March a sharply split U.S. Court of Appeals for the Federal Circuit reversed course and reinstated a win for Marine Polymer Technologies in its wound dressing patent spat with HemCon.
A sharply split federal appeals court reversed course and reinstated a $29.4 million win for Marine Polymer Technologies in its wound dressing patent spat with HemCon Medical Technologies.
The U.S. Court of Appeals for the Federal Circuit, in an en banc decision joined in full by 5 of 9 judges on the panel, ruled that the "intervening rights" of a company accused of patent infringement are only valid when patent claim language is changed during re-examination.
A trio of med-tech titans logged a win against Johnson & Johnson (NYSE:JNJ) in a long-running battle over drug-eluting coronary stent patents.
A patent spat between St. Jude Medical (NYSE:STJ) and Occlutech GmbH that morphed into a personal lawsuit against Occlutech CEO Tor Peters was dismissed by a German court, prompting Peters to call the suit "amazing and quite shocking."
St. Jude inherited the case, involving intravascular occlusion devices, after it acquired AGA Medical for more than $1 billion last year.
Here’s a roundup of companies announcing clearances and approvals from the Food & Drug Administration and foreign regulatory agencies:
U.S. Court of Appeals for the Federal Circuit granted HemCon Medical Technologies Inc. the right to continue selling its hemostatic bandages by staying an injunction against the company.
The appeals court ruling also postponed the damages payment that the Portland, Ore.-based company was ordered to pay in an ongoing patent infringement lawsuit brought by Marine Polymer Technologies Inc. in 2006 over bio-compatible polymers used in its hemostatic products.